NCT01348737

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to assess the safety, tolerability and blood concentration of AZD3839 following oral administration of single doses in healthy men and women of non-childbearing potential

Conditions

• Alzheimer's Disease
• Safety
• Tolerability
• Blood Concentration
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	AZD3839	Single Oral Dose
DRUG	AZD3839 Placebo	Single Oral Dose

Timeline

• Start date: 2011-06-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2011-05-05
• Last updated: 2012-04-06

Locations

1 site across 1 country: United Kingdom